tradingkey.logo

Biomerica Inc

BMRA
查看詳細走勢圖
2.650USD
+0.030+1.15%
收盤 12/24, 13:00美東報價延遲15分鐘
7.46M總市值
虧損本益比TTM

Biomerica Inc

2.650
+0.030+1.15%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+1.15%

5天

+10.88%

1月

+15.72%

6月

-16.14%

今年開始到現在

+10.38%

1年

+19.15%

查看詳細走勢圖

TradingKey Biomerica Inc股票評分

單位: USD 更新時間: 2025-12-24

操作建議

Biomerica Inc當前公司基本面數據相對非常健康,增長潛力較大。當前估值合理,在醫療設備與耗材行業排名150/206位。機構持股佔比非常高,中期看,股價處於平穩狀態。近一個月,市場表現較強,但基本面和技術面綜合得分較低,較強的走勢沒有得到基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Biomerica Inc評分

相關信息

行業排名
150 / 206
全市場排名
445 / 4562
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 0 分析師
--
評級
0.000
目標均價
0.00%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Biomerica Inc亮點

亮點風險
Biomerica, Inc. is a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are utilized in the analysis of blood, urine, nasal, or fecal samples for the diagnosis of various diseases, food intolerances, and other medical conditions. Its range of medical diagnostic products is sold primarily in two markets: clinical laboratories and point-of-care settings, including physicians’ offices and over-the-counter sales. It is focused on research and development efforts and is its patented diagnostic-guided therapy (DGT) product, developed on the in Foods technology platform. Its inFoods IBS product, uses a simple blood test to identify patient-specific foods that, when eliminated, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping, and constipation. Its hp+detect, a new diagnostic test for detecting Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract.
業績增長期
公司處於發展階段,最新年度總收入5.31M美元
估值合理
公司最新PE估值-1.72,處於3年歷史合理位
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉21.13K股
活躍度增加
近期活躍度增加,過去20天平均換手率0.18

Biomerica Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Biomerica Inc簡介

Biomerica, Inc. is a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are utilized in the analysis of blood, urine, nasal, or fecal samples for the diagnosis of various diseases, food intolerances, and other medical conditions. Its range of medical diagnostic products is sold primarily in two markets: clinical laboratories and point-of-care settings, including physicians’ offices and over-the-counter sales. It is focused on research and development efforts and is its patented diagnostic-guided therapy (DGT) product, developed on the in Foods technology platform. Its inFoods IBS product, uses a simple blood test to identify patient-specific foods that, when eliminated, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping, and constipation. Its hp+detect, a new diagnostic test for detecting Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract.
公司代碼BMRA
公司Biomerica Inc
CEOIrani (Zackary S)
網址https://biomerica.com/

常見問題

Biomerica Inc(BMRA)的當前股價是多少?

Biomerica Inc(BMRA)的當前股價是 2.650。

Biomerica Inc 的股票代碼是什麼?

Biomerica Inc的股票代碼是BMRA。

Biomerica Inc股票的52週最高點是多少?

Biomerica Inc股票的52週最高點是10.160。

Biomerica Inc股票的52週最低點是多少?

Biomerica Inc股票的52週最低點是2.110。

Biomerica Inc的市值是多少?

Biomerica Inc的市值是7.46M。

Biomerica Inc的淨利潤是多少?

Biomerica Inc的淨利潤為-4.97M。

現在Biomerica Inc(BMRA)的股票是買入、持有還是賣出?

根據分析師評級,Biomerica Inc(BMRA)的總體評級為--,目標價格為--。

Biomerica Inc(BMRA)股票的每股收益(EPS TTM)是多少

Biomerica Inc(BMRA)股票的每股收益(EPS TTM)是-1.538。
KeyAI